معاملات المطّلعين

EDGAR

Evoke Pharma Inc

معاملات أبلغ عنها المديرون والمسؤولون وملّاك أكثر من 10% في نماذج SEC رقم 3 و4 و5، مقروءة من XML كل إيداع. الرموز وصياغتها هي من SEC نفسها.

يجب إيداع النموذج 4 خلال يومي عمل من المعاملة، لذا قد لا تكون أحدث الصفقات قد أُودعت بعد.

النطاق: المعاملات المؤرخة في 16 نوفمبر 2025 أو بعده.

مشتريات السوق المفتوحة (الرمز P)
0 معاملات، — سهمًا
مبيعات السوق المفتوحة (الرمز S)
0 معاملات، — سهمًا

تجمع المجاميع المعاملات المودعة المدرجة؛ فهي عدّ لما أُبلغ عنه لا قياس لاتجاه.

عرض 1–37 من 37

معاملات المطّلعين، الأحدث أولًا، كما أُودعت في نماذج SEC رقم 3 و4 و5
التاريخالمُبلِّغالرمزمُكتسَب أو مُتصرَّف فيهالأسهمسعر السهم كما أُودعالقيمة (مشتقة)الأسهم المملوكة بعد المعاملةمباشرة أو غير مباشرةخانة القاعدة 10b5-1ملاحظاتالمصدر
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
مُتصرَّف فيه (D)148,15311.00
1,629,683

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 1629683.00.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

ورقة مالية مشتقة: Prefunded Warrants — الأصل الأساسي Common Stock (433,962) — سعر الممارسة 0.0001
مُتصرَّف فيه (D)433,96210.999
4,773,148.038

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 4773148.038.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

ورقة مالية مشتقة: Series A Common Stock Purchase Warrants — الأصل الأساسي Common Stock (117,019) — سعر الممارسة 8.16
مُتصرَّف فيه (D)117,0194.71
551,159.49

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 551159.49.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

ورقة مالية مشتقة: Series C Common Stock Purchase Warrants — الأصل الأساسي Common Stock (117,019) — سعر الممارسة 8.16
مُتصرَّف فيه (D)117,0194.71
551,159.49

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 551159.49.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

ورقة مالية مشتقة: Amended Series A Common Stock Purchase Warrants — الأصل الأساسي Common Stock (158,531) — سعر الممارسة 0.01
مُتصرَّف فيه (D)158,53110.99
1,742,255.69

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 1742255.69.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 19 ديسمبر 2025Nantahala Capital Management, LLC 10% ownerHarkey Wilmot B. 10% ownerMack Daniel 10% owner
J

Other acquisition or disposition (describe transaction)

ورقة مالية مشتقة: Amended Series C Common Stock Purchase Warrants — الأصل الأساسي Common Stock (250,627) — سعر الممارسة 0.01
مُتصرَّف فيه (D)250,62710.99
2,754,390.73

مشتق: الأسهم × سعر السهم. القيمة الدقيقة 2754390.73.

0غير مباشرة (I) See Footnoteلا
F1, F2
  • F1 These securities were disposed of for cash in or in connection with the merger of Evoke Pharma Inc with QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of QOL Medical, LLC.
  • F2 Nantahala Capital Management, LLC (NCM), an investment adviser to certain private funds and managed accounts (the NCM Investors) that hold the Evoke Pharma, Inc. (Issuer) securities disclosed in this statement, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B. Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.
فتح الإيداع 0001104659-25-123156 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 5.41
مُتصرَّف فيه (D)1,218——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Hill Malcolm R Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,218——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,479) — سعر الممارسة 5.41
مُتصرَّف فيه (D)1,479——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (8,750) — سعر الممارسة 4.45
مُتصرَّف فيه (D)8,750——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025GARNER CAM L Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,291) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,291——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 5.41
مُتصرَّف فيه (D)1,187——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025WIDDER KENNETH J Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,187——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322641 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,250) — سعر الممارسة 5.41
مُتصرَّف فيه (D)1,250——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025REED VICKIE S Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,250) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,250——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322638 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,218) — سعر الممارسة 5.41
مُتصرَّف فيه (D)1,218——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 4.45
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Brady Todd C Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,187) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,187——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 5.51
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322645 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Smeal Benjamin C. Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,125) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,125——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322645 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (17,291) — سعر الممارسة 5.27
مُتصرَّف فيه (D)17,291——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025CARLSON MARILYN R. Officer: Chief Medical Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (11,000) — سعر الممارسة 4.45
مُتصرَّف فيه (D)11,000——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (64,840) — سعر الممارسة 5.27
مُتصرَّف فيه (D)64,840——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (70,000) — سعر الممارسة 4.45
مُتصرَّف فيه (D)70,000——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (17,291) — سعر الممارسة 5.27
مُتصرَّف فيه (D)17,291——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025Kowieski Mark Officer: Chief Financial Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (13,000) — سعر الممارسة 4.45
مُتصرَّف فيه (D)13,000——0مباشرة (D) لا
F2
  • F2 After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) the Offer Price, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (5,833) — سعر الممارسة 5.26
مُتصرَّف فيه (D)5,833——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322646 مقروء من XML الإيداع الاعتراض على هذا الصف
17 ديسمبر 2025 أُودع في 17 ديسمبر 2025PYSZCZYMUKA GREG Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

ورقة مالية مشتقة: Stock Option (Right to Buy) — الأصل الأساسي Common Stock (1,155) — سعر الممارسة 3.453
مُتصرَّف فيه (D)1,155——0مباشرة (D) لا
F1, F2
  • F1 In connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub), Merger Sub merged with and into the Issuer, effective as of December 17, 2025 (the Effective Time), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
  • F2 Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase shares of Common Stock (Company Option) outstanding as of immediately prior to the Effective Time accelerated and became fully vested and was automatically canceled and terminated and converted into the right to receive, subject to the terms of the Merger Agreement, an amount in cash (without interest) equal to the product obtained by multiplying (i) the aggregate number of shares underlying such Company Option immediately prior to the Effective Time, by (ii) an amount equal to (x) $11.00, less (y) the per share exercise price of such Company Option.
فتح الإيداع 0001193125-25-322646 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025Hill Malcolm R Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)133——0مباشرة (D) لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322642 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025GARNER CAM L Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)2,330——0غير مباشرة (I) By Garner Investments, L.L.C.لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322643 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025Brady Todd C Director
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)27——0مباشرة (D) لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322639 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025CARLSON MARILYN R. Officer: Chief Medical Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)360——0مباشرة (D) لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322644 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025D'Onofrio Matthew J Director · Officer: Chief Executive Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)15,509——0مباشرة (D) لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322637 مقروء من XML الإيداع الاعتراض على هذا الصف
16 ديسمبر 2025 أُودع في 17 ديسمبر 2025Kowieski Mark Officer: Chief Financial Officer
U

Disposition pursuant to a tender of shares in a change of control transaction

Common Stock
مُتصرَّف فيه (D)11,815——0مباشرة (D) لا
F1
  • F1 On December 16, 2025, in connection with that certain Agreement and Plan of Merger, dated as of November 3, 2025 (the Merger Agreement), by and among the Issuer, QOL Medical, LLC (Parent) and QOL-EOS Merger Sub, Inc., a wholly owned subsidiary of Parent (Merger Sub and together with Parent, the Purchasers), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for $11.00 per share in cash (the Offer Price).
فتح الإيداع 0001193125-25-322640 مقروء من XML الإيداع الاعتراض على هذا الصف

الحائزون المؤسسيون (النموذج 13F)

لا يوجد في المخزن مركز من النموذج 13F مرتبط بهذا المُصدر. الحائز غير المرتبط بعد أو الذي لم يُودع بعد غائب، لا صفر.

حائزو 5% (الجدولان 13D و13G)

تُقرأ هنا الجداول المودعة بصيغة SEC المنظَّمة (من أواخر 2024). الجداول الأقدم نص حر ولا تُقرأ.

حائزو 5%، الأحدث حدثًا أولًا، كما أُودعت
الحائزنسبة الفئةالأسهم المحتفظ بهاتاريخ الحدثالنموذجالمصدر
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share00.0012/17/2025 أُودع في 19 ديسمبر 2025SCHEDULE 13D/Aالتعديل 5فتح الإيداع 0001104659-25-123157 الاعتراض على هذا الصف
Harkey Wilmot B. Common Stock, par value $0.0001 per share00.0012/17/2025 أُودع في 19 ديسمبر 2025SCHEDULE 13D/Aالتعديل 5فتح الإيداع 0001104659-25-123157 الاعتراض على هذا الصف
Mack Daniel Common Stock, par value $0.0001 per share00.0012/17/2025 أُودع في 19 ديسمبر 2025SCHEDULE 13D/Aالتعديل 5فتح الإيداع 0001104659-25-123157 الاعتراض على هذا الصف
Morgan Stanley Common Stock0.03111/30/2025 أُودع في 5 ديسمبر 2025SCHEDULE 13G/Aالتعديل 1فتح الإيداع 0000895421-25-000595 الاعتراض على هذا الصف
Morgan Stanley Smith Barney LLC Common Stock0.03111/30/2025 أُودع في 5 ديسمبر 2025SCHEDULE 13G/Aالتعديل 1فتح الإيداع 0000895421-25-000595 الاعتراض على هذا الصف
Klein Roger M. Common Stock, par value $0.0001 per share10.5163,000.0011/04/2025 أُودع في 12 نوفمبر 2025SCHEDULE 13Dفتح الإيداع 0001651175-25-000007 الاعتراض على هذا الصف
Krieger Charitable Trust Common Stock, par value $0.0001 per share8.3129,000.0011/04/2025 أُودع في 12 نوفمبر 2025SCHEDULE 13Dفتح الإيداع 0001651175-25-000007 الاعتراض على هذا الصف
Nantahala Capital Management, LLC Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 أُودع في 4 نوفمبر 2025SCHEDULE 13D/Aالتعديل 4فتح الإيداع 0001104659-25-106048 الاعتراض على هذا الصف
Harkey Wilmot B. Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 أُودع في 4 نوفمبر 2025SCHEDULE 13D/Aالتعديل 4فتح الإيداع 0001104659-25-106048 الاعتراض على هذا الصف
Mack Daniel Common Stock, par value $0.0001 per share15.99268,431.0011/03/2025 أُودع في 4 نوفمبر 2025SCHEDULE 13D/Aالتعديل 4فتح الإيداع 0001104659-25-106048 الاعتراض على هذا الصف
Morgan Stanley Common Stock10.5163,71808/31/2025 أُودع في 8 سبتمبر 2025SCHEDULE 13Gفتح الإيداع 0000895421-25-000528 الاعتراض على هذا الصف
Morgan Stanley Smith Barney LLC Common Stock10.5163,71808/31/2025 أُودع في 8 سبتمبر 2025SCHEDULE 13Gفتح الإيداع 0000895421-25-000528 الاعتراض على هذا الصف

النسبة هي من الفئة التي يسميها الإيداع كما صرّح بها الحائز. يُبلغ كل عضو في مجموعة عن أسهم المجموعة، لذا لا تُجمع الصفوف.

ما جرت قراءته

قُرئ 2,092,408 إيداعًا مؤرخًا من 14 يونيو 2004 إلى 13 نوفمبر 2026: النماذج 3, 3/A, 4, 4/A, 5, 5/A.

قد تكون بعض السنوات ناقصة ما دام الأرشيف قيد القراءة. سنة قليلة الإيداعات هنا لا تعني أن القليل أُودع فعلًا.

الإيداعات المقروءة حسب سنة الإيداع
سنة الإيداعالإيداعات المقروءة
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024185,386
2025235,520
2026254,737

الإيداعات السابقة لاشتراط SEC صيغة XML مُدرجة لكن غير مستخرجة.

العودة إلى Evoke Pharma Inc